225.63
-2.84 (-1.24%)
| Penutupan Terdahulu | 228.47 |
| Buka | 228.16 |
| Jumlah Dagangan | 1,566,054 |
| Purata Dagangan (3B) | 1,472,546 |
| Modal Pasaran | 38,424,788,992 |
| Harga / Pendapatan (P/E TTM) | 31.04 |
| Harga / Pendapatan (P/E Ke hadapan) | 15.60 |
| Harga / Jualan (P/S) | 2.50 |
| Harga / Buku (P/B) | 6.24 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 28 Oct 2025 |
| Margin Keuntungan | 7.88% |
| Margin Operasi (TTM) | 13.39% |
| EPS Cair (TTM) | 6.89 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 5.30% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -26.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 272.12% |
| Nisbah Semasa (MRQ) | 0.840 |
| Aliran Tunai Operasi (OCF TTM) | 2.62 B |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 2.45 B |
| Pulangan Atas Aset (ROA TTM) | 5.16% |
| Pulangan Atas Ekuiti (ROE TTM) | 19.79% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Menaik | Bercampur |
| Diagnostics & Research (Global) | Menaik | Bercampur | |
| Stok | IQVIA Holdings, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.75 |
|
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Mid Core |
| % Dimiliki oleh Orang Dalam | 1.05% |
| % Dimiliki oleh Institusi | 98.21% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 265.00 (Truist Securities, 17.45%) | Beli |
| 265.00 (Morgan Stanley, 17.45%) | Beli | |
| Median | 250.00 (10.80%) | |
| Rendah | 200.00 (Barclays, -11.36%) | Pegang |
| Purata | 242.46 (7.46%) | |
| Jumlah | 10 Beli, 3 Pegang | |
| Harga Purata @ Panggilan | 212.89 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Morgan Stanley | 02 Dec 2025 | 265.00 (17.45%) | Beli | 225.63 |
| BMO Capital | 13 Nov 2025 | 260.00 (15.23%) | Beli | 223.55 |
| TD Cowen | 03 Nov 2025 | 215.00 (-4.71%) | Pegang | 213.88 |
| Baird | 29 Oct 2025 | 258.00 (14.35%) | Beli | 217.83 |
| Citigroup | 29 Oct 2025 | 230.00 (1.94%) | Pegang | 217.83 |
| JP Morgan | 29 Oct 2025 | 255.00 (13.02%) | Beli | 217.83 |
| Stifel | 29 Oct 2025 | 254.00 (12.57%) | Beli | 217.83 |
| Truist Securities | 29 Oct 2025 | 265.00 (17.45%) | Beli | 217.83 |
| UBS | 29 Oct 2025 | 250.00 (10.80%) | Beli | 217.83 |
| HSBC | 09 Oct 2025 | 235.00 (4.15%) | Beli | 203.00 |
| Evercore ISI Group | 08 Oct 2025 | 240.00 (6.37%) | Beli | 200.60 |
| Barclays | 02 Oct 2025 | 200.00 (-11.36%) | Pegang | 204.34 |
| Jefferies | 09 Sep 2025 | 225.00 (-0.28%) | Beli | 189.64 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 02 Dec 2025 | Pengumuman | IQVIA Announces Strategic Collaboration with AWS, Naming AWS as Preferred Agentic Cloud Provider to Power Next-Generation AI Platform |
| 05 Nov 2025 | Pengumuman | Dr. William G. Kaelin Jr. joins IQVIA Board of Directors |
| 28 Oct 2025 | Pengumuman | IQVIA Reports Third-Quarter 2025 Results |
| 21 Oct 2025 | Pengumuman | IQVIA CEO Ari Bousbib to Speak at UBS Global Healthcare Conference on November 11, 2025 |
| 30 Sep 2025 | Pengumuman | IQVIA to Announce Third-Quarter 2025 Results on October 28, 2025 |
| 16 Sep 2025 | Pengumuman | IQVIA Receives WCG Pinnacle Award for Excellence in Site Relationships |
| 10 Sep 2025 | Pengumuman | IQVIA Announces Launch of Clinical Trial Financial Suite, a Next-Generation Platform for Integrated Financial Management |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |